Condition: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Lakeview Clinical Research | Guntersville, Alabama, United States | — |
| Hope Research Institute | Phoenix, Arizona, United States | — |
| Hope Research Institute | Phoenix, Arizona, United States | — |
| Interspond-Clinical Research Institute of AZ | Sun City West, Arizona, United States | — |
| Baptist Health Center For Clinical Research | Little Rock, Arkansas, United States | — |
| Sun Urology - Buena Park Office | Buena Park, California, United States | — |
| Hope clinical Research LLC | Canoga Park, California, United States | — |
| Velocity Clinical Research, Inc. | Chula Vista, California, United States | — |
| Marvel Clinical Research | Huntington Beach, California, United States | — |
| California Adult Circumcision - Alvarado La Mesa Urology Center | La Mesa, California, United States | — |
| Om Research LLC | Lancaster, California, United States | — |
| Atlantic Urology Medical Group | Long Beach, California, United States | — |
+ 362 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.